| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
|
N Engl J Med
|
2002
|
19.60
|
|
2
|
Follicular lymphoma international prognostic index.
|
Blood
|
2004
|
7.20
|
|
3
|
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
|
Lancet
|
2010
|
5.59
|
|
4
|
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.
|
Cancer Cell
|
2011
|
5.28
|
|
5
|
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
|
Blood
|
2010
|
4.97
|
|
6
|
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
|
N Engl J Med
|
2005
|
4.13
|
|
7
|
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
|
Lancet
|
2011
|
3.21
|
|
8
|
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
|
Lancet Oncol
|
2011
|
2.97
|
|
9
|
Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
|
J Clin Oncol
|
2012
|
2.56
|
|
10
|
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
|
J Clin Oncol
|
2007
|
2.17
|
|
11
|
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
|
Haematologica
|
2007
|
2.03
|
|
12
|
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
1.98
|
|
13
|
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
|
J Clin Oncol
|
2003
|
1.90
|
|
14
|
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
|
Blood
|
2012
|
1.89
|
|
15
|
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
|
J Clin Oncol
|
2006
|
1.83
|
|
16
|
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
|
Blood
|
2010
|
1.55
|
|
17
|
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2013
|
1.49
|
|
18
|
Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness.
|
Int J Cancer
|
2005
|
1.48
|
|
19
|
Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
|
J Clin Oncol
|
2011
|
1.37
|
|
20
|
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
|
Haematologica
|
2011
|
1.31
|
|
21
|
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
|
J Clin Oncol
|
2011
|
1.30
|
|
22
|
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
|
J Clin Oncol
|
2014
|
1.26
|
|
23
|
Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation.
|
Clin Immunol
|
2008
|
1.26
|
|
24
|
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.24
|
|
25
|
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
|
J Clin Oncol
|
2009
|
1.21
|
|
26
|
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
|
J Clin Oncol
|
2013
|
1.20
|
|
27
|
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
|
J Clin Oncol
|
2002
|
1.20
|
|
28
|
The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.
|
Haematologica
|
2011
|
1.15
|
|
29
|
The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
|
Pathol Biol (Paris)
|
2006
|
1.13
|
|
30
|
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
|
J Clin Oncol
|
2008
|
1.13
|
|
31
|
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.
|
Haematologica
|
2012
|
1.11
|
|
32
|
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
|
Blood
|
2003
|
1.10
|
|
33
|
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
|
Am J Hematol
|
2014
|
1.10
|
|
34
|
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
|
J Clin Oncol
|
2012
|
1.07
|
|
35
|
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.
|
Blood
|
2004
|
1.07
|
|
36
|
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
|
Blood
|
2010
|
1.05
|
|
37
|
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.
|
Haematologica
|
2013
|
1.04
|
|
38
|
Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma.
|
Am J Hematol
|
2005
|
1.00
|
|
39
|
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
|
Haematologica
|
2011
|
1.00
|
|
40
|
Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype.
|
Am J Surg Pathol
|
2002
|
0.99
|
|
41
|
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.98
|
|
42
|
TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.
|
Br J Haematol
|
2011
|
0.98
|
|
43
|
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
|
Br J Haematol
|
2010
|
0.98
|
|
44
|
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.96
|
|
45
|
Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
|
Leuk Lymphoma
|
2013
|
0.96
|
|
46
|
Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2011
|
0.96
|
|
47
|
Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
|
Cancer Biother Radiopharm
|
2008
|
0.94
|
|
48
|
S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells.
|
Blood
|
2008
|
0.93
|
|
49
|
Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
|
Genes Chromosomes Cancer
|
2013
|
0.91
|
|
50
|
Voltage-gated potassium channel antibody paraneoplastic limbic encephalitis associated with acute myeloid leukemia.
|
Case Rep Oncol
|
2013
|
0.91
|
|
51
|
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
|
Hematol Oncol
|
2011
|
0.89
|
|
52
|
Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib.
|
Lancet Oncol
|
2005
|
0.88
|
|
53
|
PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.85
|
|
54
|
PVRL2 is translocated to the TRA@ locus in t(14;19)(q11;q13)-positive peripheral T-cell lymphomas.
|
Genes Chromosomes Cancer
|
2007
|
0.84
|
|
55
|
Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
|
Genes Chromosomes Cancer
|
2012
|
0.84
|
|
56
|
Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.
|
Br J Haematol
|
2009
|
0.83
|
|
57
|
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.
|
Genes Chromosomes Cancer
|
2013
|
0.82
|
|
58
|
Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
|
Eur J Haematol
|
2014
|
0.82
|
|
59
|
Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
60
|
Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review.
|
Mycopathologia
|
2014
|
0.80
|
|
61
|
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
|
Haematologica
|
2013
|
0.80
|
|
62
|
Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen.
|
Clin Lymphoma
|
2005
|
0.80
|
|
63
|
Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era.
|
Leuk Lymphoma
|
2015
|
0.79
|
|
64
|
Eosinophilic leukemia associated with t(2;5)(p23;q31).
|
Cancer Genet Cytogenet
|
2002
|
0.79
|
|
65
|
Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.
|
Genes Chromosomes Cancer
|
2011
|
0.79
|
|
66
|
Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.78
|
|
67
|
Human monocytes synthesize hyaluronidase.
|
Br J Haematol
|
2002
|
0.78
|
|
68
|
Unusual complex hyperdiploid karyotypes in myelodysplastic syndromes.
|
Cancer Genet Cytogenet
|
2006
|
0.78
|
|
69
|
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
|
Transfusion
|
2012
|
0.78
|
|
70
|
Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
71
|
Epidemiology, pathology and treatment of non-follicular indolent lymphomas.
|
Leuk Lymphoma
|
2008
|
0.77
|
|
72
|
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
|
Eur J Cancer
|
2012
|
0.77
|
|
73
|
Recurrent disruption of the Imu splice donor site in t(14;18) positive lymphomas: a potential molecular basis for aberrant downstream class switch recombination.
|
Genes Chromosomes Cancer
|
2007
|
0.77
|
|
74
|
Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
|
Haematologica
|
2008
|
0.76
|
|
75
|
Severe acquired neutropenia associated with anti-proteinase 3 antibodies.
|
Acta Haematol
|
2011
|
0.76
|
|
76
|
Does enhanced CT influence the biological GTV measurement on FDG-PET images?
|
Radiother Oncol
|
2013
|
0.75
|
|
77
|
Dose dance in lymphomas.
|
Lancet Oncol
|
2008
|
0.75
|
|
78
|
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone: until what age?
|
Leuk Lymphoma
|
2012
|
0.75
|
|
79
|
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
80
|
Invasive aspergillosis in neutropenic patients during hospital renovation: effectiveness of mechanical preventive measures in a prospective cohort of 438 patients.
|
Mycopathologia
|
2015
|
0.75
|
|
81
|
[Clinical application of gene-expression profiling in lymphome].
|
Med Sci (Paris)
|
2004
|
0.75
|
|
82
|
Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
83
|
Secondary Philadelphia chromosome in a patient with acute lymphoblastic leukemia.
|
Cancer Genet Cytogenet
|
2004
|
0.75
|
|
84
|
Brain perfusion in adult patients with acute myeloblastic leukemia before and after cytosine arabinoside.
|
Mol Imaging Biol
|
2011
|
0.75
|
|
85
|
Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes.
|
Leuk Res
|
2012
|
0.75
|